Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recombinant protein vaccines, a proven approach against coronavirus pandemics
Jeroen Pollet, Wen‐Hsiang Chen, Ulrich Strych
Advanced Drug Delivery Reviews (2021) Vol. 170, pp. 71-82
Open Access | Times Cited: 227

Showing 1-25 of 227 citing articles:

Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Jian Liu, Minyang Fu, Manni Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 448
COVID-19 vaccine development: milestones, lessons and prospects
Maochen Li, Han Wang, Lili Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 331
SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants
Daniel Martínez-Flores, Jesús Zepeda–Cervantes, Adolfo Cruz-Reséndiz, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 211
SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama
Vaccines (2023) Vol. 11, Iss. 3, pp. 682-682
Open Access | Times Cited: 59
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
Fatemeh Bayani, Negin Safaei Hashkavaei, Sareh Arjmand, et al.
Progress in Biophysics and Molecular Biology (2023) Vol. 178, pp. 32-49
Open Access | Times Cited: 40
Malaria vaccines: a new era of prevention and control
Patrick E. Duffy, J. Patrick Gorres, Sara A. Healy, et al.
Nature Reviews Microbiology (2024) Vol. 22, Iss. 12, pp. 756-772
Closed Access | Times Cited: 15
Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy
Popat Mohite, Vaishnavi Yadav, Ramdas Pandhare, et al.
ACS Omega (2024)
Open Access | Times Cited: 14
Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis
Xiaodi Wu, Ke Xu, Ping Zhan, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 14
Integrating plant molecular farming and materials research for next-generation vaccines
Young Hun Chung, Derek C. Church, Edward C. Koellhoffer, et al.
Nature Reviews Materials (2021) Vol. 7, Iss. 5, pp. 372-388
Open Access | Times Cited: 97
SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice
Jeroen Pollet, Wen‐Hsiang Chen, Leroy Versteeg, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 17, Iss. 8, pp. 2356-2366
Open Access | Times Cited: 90
Current and future nanoparticle vaccines for COVID-19
Mai N. Vu, Hannah G. Kelly, Stephen J. Kent, et al.
EBioMedicine (2021) Vol. 74, pp. 103699-103699
Open Access | Times Cited: 80
Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate
Wen‐Hsiang Chen, Junfei Wei, Rakhi Kundu, et al.
Biochimica et Biophysica Acta (BBA) - General Subjects (2021) Vol. 1865, Iss. 6, pp. 129893-129893
Open Access | Times Cited: 61
A Summary of the SARS-CoV-2 Vaccines and Technologies Available or under Development
Zainalabideen A. Abdulla, Sharaf M. Al-Bashir, Noor S. Al-Salih, et al.
Pathogens (2021) Vol. 10, Iss. 7, pp. 788-788
Open Access | Times Cited: 58
A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19
Essa M. Saied, Yousra A. El‐Maradny, Alaa A. Osman, et al.
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1759-1759
Open Access | Times Cited: 56
Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Fuxing Lou, Maochen Li, Zehan Pang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 54
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva, et al.
The Lancet Regional Health - Americas (2022) Vol. 18, pp. 100423-100423
Open Access | Times Cited: 39
Modeling SARS-CoV-2 spike/ACE2 protein–protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context
Vincenzo Tragni, Francesca Preziusi, Luna Laera, et al.
The EPMA Journal (2022) Vol. 13, Iss. 1, pp. 149-175
Open Access | Times Cited: 37
Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern
Jeroen Pollet, Ulrich Strych, Wen‐Hsiang Chen, et al.
Vaccine (2022) Vol. 40, Iss. 26, pp. 3655-3663
Open Access | Times Cited: 37
The Promising Potential of Reverse Vaccinology-Based Next-Generation Vaccine Development over Conventional Vaccines against Antibiotic-Resistant Bacteria
Kanwal Khalid, Chit Laa Poh
Vaccines (2023) Vol. 11, Iss. 7, pp. 1264-1264
Open Access | Times Cited: 33
Herd Immunity to Fight Against COVID-19: A Narrative Review
Yasha N Suryawanshi, Dalia Biswas
Cureus (2023)
Open Access | Times Cited: 28
Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development
Qiaonan Hong, Jian Liu, Yuquan Wei, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1218-1218
Open Access | Times Cited: 25
Oral Vaccines: A Better Future of Immunization
Keith Wai-Yeung Kwong, Ying Xin, Nelson Cheuk-Yin Lai, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1232-1232
Open Access | Times Cited: 25
Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine
Ehsan Mostafavi, Sana Eybpoosh, Mohammad Karamouzian, et al.
JAMA Network Open (2023) Vol. 6, Iss. 5, pp. e2310302-e2310302
Open Access | Times Cited: 21
From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access
Peter J. Hotez, Rakesh Adhikari, Wen‐Hsiang Chen, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 495-500
Open Access | Times Cited: 21
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Congrui Zhu, Shengmei Pang, Jiaqi Liu, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 403-423
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top